The flunitrazepam abuse prevention program at a general hospital in Taiwan: A descriptive study

Winston W. Shen, Cindy Chang, Wen Chieh Hsieh, Chen Jung Yeh, Fang Y. Chiu, Yao Chin Chuang

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

The Bureau of Controlled Drugs at Ministry of Health, Executive Yuan in Taiwan announced, on 1 April 2000, the schedules of controlled drugs with abuse potential and implemented a policy on 1 October 2000 to control them. Flunitrazepam (FM2), along with other two benzodiazepines (triazolam and brotizolam), is placed on Schedule III. The aim of the present study was to analyze the pattern of flunitrazepam prescriptions across all medical subspecialty departments at Taipei Medical University-Wan Fang Hospital (TMU-WFH), Taiwan. We analyzed 1170 prescriptions over 12 month period from 1 July 2000 to 31 May 2001. All prescription data were divided into three 4 month periods: period I was when the flunitrazepam prescription was not controlled, period II represented the time when flunitrazepam was placed on Schedule III and when physicians were required to use a special duplicated prescription form and period III was when the TMU-WFH started to set a stricter control for the prescription of flunitrazepam. The results indicated that the number of flunitrazepam prescriptions during period III had decreased significantly compared with period I (P ≤ 0.05). Eventually, 45.7% of flunitrazepam-medicated patients were followed up monthly with a restriction of their flunitrazepam supply to no more than 14 days, 22.9% of patients were followed up fortnightly at clinics with a 14 day supply of flunitrazepam, 15.7% were followed up fortnightly with a 14 day restriction of flunitrazepam plus a non-flunitrazepan benzodiazepine supplement, 10.7% were referred to clinics within the Department of Psychiatry and 5% were switched from flunitrazepam to other drugs.
原文英語
頁(從 - 到)425-430
頁數6
期刊Psychiatry and Clinical Neurosciences
56
發行號4
DOIs
出版狀態已發佈 - 2002

指紋

Flunitrazepam
Taiwan
General Hospitals
Prescriptions
Appointments and Schedules
brotizolam
Benzodiazepines
Triazolam
Pharmaceutical Preparations
Substance-Related Disorders
Psychiatry

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology

引用此文

The flunitrazepam abuse prevention program at a general hospital in Taiwan : A descriptive study. / Shen, Winston W.; Chang, Cindy; Hsieh, Wen Chieh; Yeh, Chen Jung; Chiu, Fang Y.; Chuang, Yao Chin.

於: Psychiatry and Clinical Neurosciences, 卷 56, 編號 4, 2002, p. 425-430.

研究成果: 雜誌貢獻文章

Shen, Winston W. ; Chang, Cindy ; Hsieh, Wen Chieh ; Yeh, Chen Jung ; Chiu, Fang Y. ; Chuang, Yao Chin. / The flunitrazepam abuse prevention program at a general hospital in Taiwan : A descriptive study. 於: Psychiatry and Clinical Neurosciences. 2002 ; 卷 56, 編號 4. 頁 425-430.
@article{d6f2ca4b9ad14988ac7067610591c4cf,
title = "The flunitrazepam abuse prevention program at a general hospital in Taiwan: A descriptive study",
abstract = "The Bureau of Controlled Drugs at Ministry of Health, Executive Yuan in Taiwan announced, on 1 April 2000, the schedules of controlled drugs with abuse potential and implemented a policy on 1 October 2000 to control them. Flunitrazepam (FM2), along with other two benzodiazepines (triazolam and brotizolam), is placed on Schedule III. The aim of the present study was to analyze the pattern of flunitrazepam prescriptions across all medical subspecialty departments at Taipei Medical University-Wan Fang Hospital (TMU-WFH), Taiwan. We analyzed 1170 prescriptions over 12 month period from 1 July 2000 to 31 May 2001. All prescription data were divided into three 4 month periods: period I was when the flunitrazepam prescription was not controlled, period II represented the time when flunitrazepam was placed on Schedule III and when physicians were required to use a special duplicated prescription form and period III was when the TMU-WFH started to set a stricter control for the prescription of flunitrazepam. The results indicated that the number of flunitrazepam prescriptions during period III had decreased significantly compared with period I (P ≤ 0.05). Eventually, 45.7{\%} of flunitrazepam-medicated patients were followed up monthly with a restriction of their flunitrazepam supply to no more than 14 days, 22.9{\%} of patients were followed up fortnightly at clinics with a 14 day supply of flunitrazepam, 15.7{\%} were followed up fortnightly with a 14 day restriction of flunitrazepam plus a non-flunitrazepan benzodiazepine supplement, 10.7{\%} were referred to clinics within the Department of Psychiatry and 5{\%} were switched from flunitrazepam to other drugs.",
keywords = "Benzodiazepine, Controlled drugs, Flunitrazepam, Schedule III",
author = "Shen, {Winston W.} and Cindy Chang and Hsieh, {Wen Chieh} and Yeh, {Chen Jung} and Chiu, {Fang Y.} and Chuang, {Yao Chin}",
year = "2002",
doi = "10.1046/j.1440-1819.2002.01032.x",
language = "English",
volume = "56",
pages = "425--430",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The flunitrazepam abuse prevention program at a general hospital in Taiwan

T2 - A descriptive study

AU - Shen, Winston W.

AU - Chang, Cindy

AU - Hsieh, Wen Chieh

AU - Yeh, Chen Jung

AU - Chiu, Fang Y.

AU - Chuang, Yao Chin

PY - 2002

Y1 - 2002

N2 - The Bureau of Controlled Drugs at Ministry of Health, Executive Yuan in Taiwan announced, on 1 April 2000, the schedules of controlled drugs with abuse potential and implemented a policy on 1 October 2000 to control them. Flunitrazepam (FM2), along with other two benzodiazepines (triazolam and brotizolam), is placed on Schedule III. The aim of the present study was to analyze the pattern of flunitrazepam prescriptions across all medical subspecialty departments at Taipei Medical University-Wan Fang Hospital (TMU-WFH), Taiwan. We analyzed 1170 prescriptions over 12 month period from 1 July 2000 to 31 May 2001. All prescription data were divided into three 4 month periods: period I was when the flunitrazepam prescription was not controlled, period II represented the time when flunitrazepam was placed on Schedule III and when physicians were required to use a special duplicated prescription form and period III was when the TMU-WFH started to set a stricter control for the prescription of flunitrazepam. The results indicated that the number of flunitrazepam prescriptions during period III had decreased significantly compared with period I (P ≤ 0.05). Eventually, 45.7% of flunitrazepam-medicated patients were followed up monthly with a restriction of their flunitrazepam supply to no more than 14 days, 22.9% of patients were followed up fortnightly at clinics with a 14 day supply of flunitrazepam, 15.7% were followed up fortnightly with a 14 day restriction of flunitrazepam plus a non-flunitrazepan benzodiazepine supplement, 10.7% were referred to clinics within the Department of Psychiatry and 5% were switched from flunitrazepam to other drugs.

AB - The Bureau of Controlled Drugs at Ministry of Health, Executive Yuan in Taiwan announced, on 1 April 2000, the schedules of controlled drugs with abuse potential and implemented a policy on 1 October 2000 to control them. Flunitrazepam (FM2), along with other two benzodiazepines (triazolam and brotizolam), is placed on Schedule III. The aim of the present study was to analyze the pattern of flunitrazepam prescriptions across all medical subspecialty departments at Taipei Medical University-Wan Fang Hospital (TMU-WFH), Taiwan. We analyzed 1170 prescriptions over 12 month period from 1 July 2000 to 31 May 2001. All prescription data were divided into three 4 month periods: period I was when the flunitrazepam prescription was not controlled, period II represented the time when flunitrazepam was placed on Schedule III and when physicians were required to use a special duplicated prescription form and period III was when the TMU-WFH started to set a stricter control for the prescription of flunitrazepam. The results indicated that the number of flunitrazepam prescriptions during period III had decreased significantly compared with period I (P ≤ 0.05). Eventually, 45.7% of flunitrazepam-medicated patients were followed up monthly with a restriction of their flunitrazepam supply to no more than 14 days, 22.9% of patients were followed up fortnightly at clinics with a 14 day supply of flunitrazepam, 15.7% were followed up fortnightly with a 14 day restriction of flunitrazepam plus a non-flunitrazepan benzodiazepine supplement, 10.7% were referred to clinics within the Department of Psychiatry and 5% were switched from flunitrazepam to other drugs.

KW - Benzodiazepine

KW - Controlled drugs

KW - Flunitrazepam

KW - Schedule III

UR - http://www.scopus.com/inward/record.url?scp=0036342527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036342527&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1819.2002.01032.x

DO - 10.1046/j.1440-1819.2002.01032.x

M3 - Article

C2 - 12109961

AN - SCOPUS:0036342527

VL - 56

SP - 425

EP - 430

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 4

ER -